Showing results (331-340 of 1,072) with videos related to
Sort By:
Pageof 108
Stroke|January 5, 2008
A systematic review of outcomes in patients with staged carotid artery stenting and coronary artery bypass graft surgeryLuis A Guzman, Marco A Costa, Dominick J Angiolillo, et al.Clinical Pharmacokinetics|April 28, 2023
Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of BentracimabLuis Ortega-Paz, Salvatore Giordano, Francesco Franchi, et al.Circulation. Cardiovascular Interventions|July 9, 2015
Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot StudyRon Waksman, Juan Maya, Dominick J Angiolillo, et al.Journal of the American College of Cardiology|April 10, 2007
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectivesDominick J Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, et al.Expert Review of Cardiovascular Therapy|November 3, 2023
Bivalirudin in acute coronary syndromesMattia Galli, Marco Bernardi, Luis Ortega-Paz, et al.European Heart Journal. Acute Cardiovascular Care|January 3, 2024
Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelinesAntonio Landi, Victor Aboyans, Dominick J Angiolillo, et al.Thrombosis and Haemostasis|February 16, 2018
Impact of Multidrug Resistance Protein-4 Inhibitors on Modulating Platelet Function and High on-Aspirin Treatment Platelet ReactivityLaura Alemanno, Isabella Massimi, Vanessa Klaus, et al.American Heart Journal|August 3, 2020
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trialYi Li, Quanmin Jing, Bing Wang, et al.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|November 18, 2016
The Rationale for and Clinical Pharmacology of Prasugrel 5 mgJoseph A Jakubowski, David Erlinge, Dimitrios Alexopoulos, et al.Circulation. Cardiovascular Interventions|January 13, 2018
Decision Analytic Markov Model Weighting Expected Benefits and Current Limitations of First-Generation Bioresorbable Vascular Scaffolds: Implications for Manufacturers and Next Device IterationsDavide Capodanno, Sergio Buccheri, Sara Romano, et al.Pageof 108